p53-specific CD8+ T-cell responses in individuals with cutaneous squamous cell carcinoma

British Journal of Dermatology

Volumn 153, Issue 5, 2005, Pages 987-991

  Black, A P ^a   Bailey, A ^a   Jones, L ^a   Turner, R J ^b   Hollowood, K ^a   Ogg, Graham S ^a,b  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^b CHURCHILL HOSPITAL   (United Kingdom)

Author keywords

p53; Squamous cell carcinoma; T cells

Indexed keywords

CD8 ANTIGEN; EPITOPE; GAMMA INTERFERON; HLA A ANTIGEN; MUTANT PROTEIN; PROTEIN P53; TUMOR ANTIGEN;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FREQUENCY ANALYSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOTHESIS; IMMUNE RESPONSE; IMMUNOREACTIVITY; LYMPHOCYTIC INFILTRATION; MALE; MUTATION; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SKIN CARCINOMA; SQUAMOUS CELL CARCINOMA; STATISTICAL SIGNIFICANCE; T LYMPHOCYTE ACTIVATION;

CARCINOMA, SQUAMOUS CELL; CD8-POSITIVE T-LYMPHOCYTES; EPITOPES, T-LYMPHOCYTE; FEMALE; HLA-A ANTIGENS; HUMANS; INTERFERON TYPE II; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; SKIN NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 27544492730     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2005.06878.x     Document Type: Article

References (29)

1. Chowdary DR, Dermody JJ, Jha KK et al. Accumulation of p53 in a mutant cell line defective in the ubiquitin pathway. Mol Cell Biol 1994; 14:1997-2003.
2. Soussi T. The p53 tumor suppressor gene: from molecular biology to clinical investigation. Ann NY Acad Sci 2000; 910:121-37.
3. Hollstein M, Sidransky D, Vogelstein B et al. p53 mutations in human cancers. Science 1991; 253:49-53.
4. Ziegler A, Jonason AS, Leffell DJ et al. Sunburn and p53 in the onset of skin cancer. Nature 1994; 372:773-6.
5. Hartevelt MM, Bavinck JN, Kootte AM et al. Incidence of skin cancer after renal transplantation in the Netherlands. Transplantation 1990; 49:506-9.
6. Patel A, Halliday GM, Barnetson RS. CD4+ T lymphocyte infiltration correlates with regression of a UV-induced squamous cell carcinoma. J Dermatol Sci 1995; 9:12-19.
7. Halliday GM, Patel A, Hunt MJ et al. Spontaneous regression of human melanoma/nonmelanoma skin cancer: association with infiltrating CD4+ T cells. World J Surg 1995; 19:352-8.
8. Houbiers JG, Nijman HW, van der Burg SH et al. In vitro induction of human cytotoxic T lymphocyte responses against peptides of mutant and wild-type p53. Eur J Immunol 1993; 23:2072-7.
9. Nijman HW, Houbiers JG, van der Burg SH et al. Characterization of cytotoxic T lymphocyte epitopes of a self-protein, p53, and a non-self-protein, influenza matrix: relationship between major histocompatibility complex peptide binding affinity and immune responsiveness to peptides. J Immunother 1993; 14:121-6.
10. Zeh HJ 3rd, Leder GH, Lotze MT et al. Flow-cytometric determination of peptide-class I complex formation. Identification of p53 peptides that bind to HLA-A2. Hum Immunol 1994; 39:79-86.
11. Stuber G, Leder GH, Storkus WT et al. Identification of wild-type and mutant p53 peptides binding to HLA-A2 assessed by a peptide loading-deficient cell line assay and a novel major histocompatibility complex class I peptide binding assay. Eur J Immunol 1994; 24:765-8.
12. Gnjatic S, Bressac-de Paillerets B, Guillet JG et al. Mapping and ranking of potential cytotoxic T epitopes in the p53 protein: effect of mutations and polymorphism on peptide binding to purified and refolded HLA molecules. Eur J Immunol 1995; 25: 1638-42.
13. McArdle SE, Rees RC, Mulcahy KA et al. Induction of human cytotoxic T lymphocytes that preferentially recognise tumour cells bearing a conformational p53 mutant. Cancer Immunol Immunother 2000; 49:417-25.
14. Ferries E, Connan F, Pages F et al. Identification of p53 peptides recognized by CD8(+) T lymphocytes from patients with bladder cancer. Hum Immunol 2001; 62:791-8.
15. Petersen TR, Buus S, Brunak S et al. Identification and design of p53-derived HLA-A2-binding peptides with increased CTL immunogenicity. Scand J Immunol 2001; 53:357-64.
16. Petersen TR, Bregenholta S, Pedersen LO et al. Human p53(264-272) HLA-A2 binding peptide is an immunodominant epitope in DNA-immunized HLA-A2 transgenic mice. Cancer Lett 1999; 137:183-91.
17. Black AP, Ogg GS. The role of p53 in the immunobiology of cutaneous squamous cell carcinoma. Clin Exp Immunol 2003; 132:379-84.
18. Gnjatic S, Cai Z, Viguier M et al. Accumulation of the p53 protein allows recognition by human CTL of a wild-type p53 epitope presented by breast carcinomas and melanomas. J Immunol 1998; 160:328-33.
19. Ropke M, Hald J, Guldberg P et al. Spontaneous human squamous cell carcinomas are killed by a human cytotoxic T lymphocyte clone recognizing a wild-type p53-derived peptide. Proc Natl Acad Sci USA 1996; 93:14704-7.
20. Chikamatsu K, Nakano K, Storkus WJ et al. Generation of anti-p53 cytotoxic T lymphocytes from human peripheral blood using autologous dendritic cells. Clin Cancer Res 1999; 5:1281-8.
21. Eura M, Chikamatsu K, Katsura F et al. A wild-type sequence p53 peptide presented by HLA-A24 induces cytotoxic T lymphocytes that recognize squamous cell carcinomas of the head and neck. Clin Cancer Res 2000; 6:979-86.
22. Barfoed AM, Petersen TR, Kirkin AF et al. Cytotoxic T-lymphocyte clones, established by stimulation with the HLA-A2 binding p5365-73 wild type peptide loaded on dendritic cells in vitro, specifically recognize and lyse HLA-A2 tumour cells overexpressing the p53 protein. Scand J Immunol 2000; 51:128-33.
23. Nikitina EY, Clark JI, van Beynen J et al. Dendritic cells transduced with full-length wild-type p53 generate antitumor cytotoxic T lymphocytes from peripheral blood of cancer patients. Clin Cancer Res 2001; 7:127-35.
24. Wurtzen PA, Pedersen LO, Poulsen HS et al. Specific killing of p53 mutated tumor cell lines by a cross-reactive human HLA-A2-restricted p53-specific CTL line. Int J Cancer 2001; 93:855-61.
25. Wurtzen PA, Claesson MH. A HLA-A2 restricted human CTL line recognizes a novel tumor cell expressed p53 epitope. Int J Cancer 2002; 99:568-72.
26. Hoffmann TK, Donnenberg AD, Finkelstein SD et al. Frequencies of tetramer+ T cells specific for the wild-type sequence p53(264-272) peptide in the circulation of patients with head and neck cancer. Cancer Res 2002; 62:3521-9.
27. Hernandez J, Lee PP, Davis MM et al. The use of HLA A2.1/p53 peptide tetramers to visualize the impact of self tolerance on the TCR repertoire. J Immunol 2000; 164:596-602.
28. Hoffmann TK, Loftus DJ, Nakano K et al. The ability of variant peptides to reverse the nonresponsiveness of T lymphocytes to the wild-type sequence p53(264-272) epitope. J Immunol 2002; 168:1338-47.
29. Bertholet S, Iggo R, Corradin G. Cytotoxic T lymphocyte responses to wild-type and mutant mouse p53 peptides. Eur J Immunol 1997; 27:798-801.